These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33925284)

  • 1. HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review.
    Kjeldsen EW; Nordestgaard LT; Frikke-Schmidt R
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
    Negi S; Ballantyne CM
    J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities.
    Kypreos KE; Bitzur R; Karavia EA; Xepapadaki E; Panayiotakopoulos G; Constantinou C
    Angiology; 2019 Mar; 70(3):197-209. PubMed ID: 29862840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.
    Hersberger M; von Eckardstein A
    Drugs; 2003; 63(18):1907-45. PubMed ID: 12930163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J;
    Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal therapy of low levels of high density lipoprotein-cholesterol.
    Kashyap ML; Tavintharan S; Kamanna VS
    Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atheroprotective effects of HDL: beyond reverse cholesterol transport.
    Feig JE; Shamir R; Fisher EA
    Curr Drug Targets; 2008 Mar; 9(3):196-203. PubMed ID: 18336237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of HDL in those with diabetes.
    Santos-Gallego CG; Rosenson RS
    Curr Cardiol Rep; 2014 Sep; 16(9):512. PubMed ID: 25199216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?
    Rosenson RS
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):777-82. PubMed ID: 26966281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
    Szapary PO; Rader DJ
    Curr Opin Pharmacol; 2001 Apr; 1(2):113-20. PubMed ID: 11714084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
    Davidson MH
    Am Heart Hosp J; 2007; 5(4):210-6. PubMed ID: 17982304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism.
    Rader DJ
    Am J Cardiol; 2003 Apr; 91(7A):18E-23E. PubMed ID: 12679199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.